Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ACNE
MCID: ACN011
MIFTS: 59

Acne (ACNE)

Categories: Endocrine diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Acne

About this section

MalaCards integrated aliases for Acne:

Name: Acne 11 75 28 41 14 63 16 31 33
Acne Vulgaris 11 75 53 43 14 31 33
Acne Varioliformis 11 31
Frontalis Acne 11

Classifications:

MalaCards categories:
Anatomical: Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:6543
ICD9CM 34 706.0
MeSH 43 D000152
SNOMED-CT 68 11381005 201210008
UMLS 71 C0152249 C0702166
Sources

Summaries for Acne

About this section

MedlinePlus: 41 Acne is a common skin disease that causes pimples. Pimples form when hair follicles under your skin clog up. Most pimples form on the face, neck, back, chest, and shoulders. Anyone can get acne, but it is common in teenagers and young adults. It is not serious, but it can cause scars. No one knows exactly what causes acne. Hormone changes, such as those during the teenage years and pregnancy, probably play a role. There are many myths about what causes acne. Chocolate and greasy foods are often blamed, but there is little evidence that foods have much effect on acne in most people. Another common myth is that dirty skin causes acne; however, blackheads and pimples are not caused by dirt. Stress doesn't cause acne, but stress can make it worse. If you have acne: Clean your skin gently Try not to touch your skin Avoid the sun Treatments for acne include medicines and creams. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Acne, also known as acne vulgaris, is related to sapho syndrome and rosacea, and has symptoms including pruritus and exanthema. An important gene associated with Acne is NCSTN (Nicastrin), and among its related pathways/superpathways are Innate Immune System and Prolactin Signaling. The drugs Levoleucovorin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, ovary and thyroid, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and neoplasm

PubMed Health : 63 Acne: Most teenagers will have pimples at some point. Some only have a few small pimples that soon go away again. Others develop more severe, persistent and clearly visible acne. This can be very distressing, particularly in puberty. But there are a number of things that can be done about acne, although patience is needed. This information is about acne in teenagers and young adults, known as “common acne or acne vulgaris.

Disease Ontology: 11 A sebaceous gland disease characterized by areas of blackheads, whiteheads, pimples, greasy skin, and possibly scarring.

Wikipedia: 75 Acne, also known as acne vulgaris, is a long-term skin condition that occurs when dead skin cells and... more...
Sources

Related Diseases for Acne

About this section

Diseases in the Acne family:

Acne, Adult

Diseases related to Acne via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1055)
# Related Disease Score Top Affiliating Genes
1 sapho syndrome 33.0 TNF PSTPIP1 CXCL8
2 rosacea 32.7 TNF TLR2 IL1B CXCL8
3 hidradenitis suppurativa 32.7 TNF PSTPIP1 PSENEN PSEN1 NCSTN IL1B
4 polycystic ovary syndrome 32.3 SRD5A1 SHBG PRL INS IGF1
5 dowling-degos disease 32.3 PSENEN PSEN1 NCSTN
6 hyperandrogenism 32.1 SRD5A1 SHBG PRL INS IGF1
7 neutrophilic dermatosis, acute febrile 31.9 TNF PSTPIP1 IL1B CXCL8
8 behcet syndrome 31.7 TNF TLR2 PSTPIP1 IL1B IL1A CXCL8
9 hidradenitis 31.6 TNF PSTPIP1 PSENEN PSEN1 NCSTN IL1B
10 synovitis 31.5 TNF IL1B IL1A CXCL8
11 dermatitis 31.5 TNF IL1B IL1A CXCL8
12 pyoderma 31.4 TNF PSTPIP1 IL1B CXCL8
13 seborrheic dermatitis 31.4 TNF TLR2 SHBG IL1A DEFB4A CXCL8
14 bone inflammation disease 31.4 TNF TLR2 INS IL1B IL1A CXCL8
15 pyoderma gangrenosum 31.4 TNF PSTPIP1 IL1B CXCL8
16 skin disease 31.4 TNF TLR2 SRD5A1 NCSTN INS IL1B
17 alopecia 31.2 TNF SRD5A1 SHBG PRL IL1B IL1A
18 adult syndrome 31.1 TNF INS IGF1
19 osteomyelitis 31.1 TNF TLR2 IL1B IL1A CXCL8
20 pustulosis of palm and sole 31.1 TNF PSTPIP1 CXCL8
21 exanthem 31.1 TNF IL1B CXCL8
22 psoriasis 31.1 TNF TLR2 IL1B IL1A DEFB4A CXCL8
23 androgenic alopecia 31.1 SRD5A1 SHBG PRL INS IGF1
24 dermatitis, atopic 31.0 TNF TLR2 IL1B IL1A DEFB4A CXCL8
25 lipoid congenital adrenal hyperplasia 31.0 SRD5A1 SHBG PRL INS IGF1
26 chronic recurrent multifocal osteomyelitis 30.9 TNF PSTPIP1 IL1B
27 acanthosis nigricans 30.9 SHBG INS IGF1
28 blepharitis 30.8 TNF IL1B CXCL8
29 bowel dysfunction 30.8 TNF INS IL1B
30 insulin-like growth factor i 30.8 SHBG PRL INS IGF1
31 crohn's disease 30.8 TNF TLR2 IL1B CXCL8
32 contact dermatitis 30.8 TNF TLR2 IL1B IL1A DEFB4A CXCL8
33 cellulitis 30.8 TNF INS IL1B DEFB4A CXCL8
34 hyperprolactinemia 30.8 SHBG PRL INS IGF1
35 amenorrhea 30.8 SHBG PRL INS IGF1
36 inflammatory bowel disease 1 30.8 TNF TLR2 IL1B DEFB4A
37 anxiety 30.7 TNF PRL INS IL1B IGF1 CXCL8
38 irritant dermatitis 30.7 TNF IL1B IL1A CXCL8
39 psoriatic arthritis 30.7 TNF TLR2 IL1B IL1A
40 spondyloarthropathy 30.7 TNF IL1B CXCL8
41 keratitis, hereditary 30.7 TNF TLR2 IL1B CXCL8
42 erythema nodosum 30.7 TNF IL1B IL1A CXCL8
43 leptin deficiency or dysfunction 30.7 TNF INS IL1B IGF1
44 arthritis 30.6 TNF TLR2 PSTPIP1 IL1B IL1A CXCL8
45 osteoarthritis 30.6 TNF IL1B IL1A IGF1 CXCL8
46 purpura 30.6 TNF IL1B CXCL8
47 lipid metabolism disorder 30.6 TNF SHBG INS IL1B IGF1 GGT1
48 allergic contact dermatitis 30.6 TNF IL1B DEFB4A CXCL8
49 anovulation 30.6 SRD5A1 SHBG PRL INS IGF1
50 headache 30.5 TNF PRL CXCL8

Graphical network of the top 20 diseases related to Acne:



Diseases related to Acne
Sources

Symptoms & Phenotypes for Acne

About this section

UMLS symptoms related to Acne:


pruritus; exanthema

GenomeRNAi Phenotypes related to Acne according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 CAT CXCL8 DEFB1 DEFB4A GATA6 GGT1
2 no effect GR00402-S-2 10.2 CAT DEFB1 DEFB4A GATA6 GGT1 IGF1
3 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 CAT CXCL8 INS TNF

MGI Mouse Phenotypes related to Acne:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.02 CAT IGF1 IL1A IL1B NCSTN PRL
2 immune system MP:0005387 10 DEFB1 DEFB4A GGT1 IGF1 IL1A IL1B
3 endocrine/exocrine gland MP:0005379 9.96 GGT1 IGF1 INS PRL PSEN1 PSTPIP1
4 renal/urinary system MP:0005367 9.92 DEFB1 GGT1 IGF1 INS NCSTN PSEN1
5 hematopoietic system MP:0005397 9.77 DEFB4A GATA6 GGT1 IGF1 IL1A IL1B
6 integument MP:0010771 9.36 GGT1 IGF1 IL1A IL1B INS NCSTN
Sources

Drugs & Therapeutics for Acne

About this section

PubMed Health treatment related to Acne: 63

People with acne often try out different things to improve the appearance of their skin . There are a lot of different recommendations when it comes to acne, involving things like facial toners, sunlight and specific diets. There are also a number of medications for acne . Some are applied to the skin , some are swallowed. Because you can buy them without a prescription, many of the products are heavily marketed. But advert ising campaigns often create unrealistic expectations. Some treatment approaches and medications have been proven to effectively reduce acne, while others have not. Unfortunately there are only a few good-quality studies comparing the various treatments with each other. So it is not possible to tell whether certain products are more effective than others. Most products have to be used for a long time before there is a noticeable improvement. And some have strong side effects.

Drugs for Acne (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Calcipotriol Approved Phase 4 112965-21-6 5288783
4
Lymecycline Approved, Investigational Phase 4 992-21-2
5
Adapalene Approved Phase 4 106685-40-9 60164
6
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
7
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Prilocaine Approved Phase 4 721-50-6 4906
10
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
11
Ethinylestradiol Approved Phase 4 57-63-6 5991
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
14
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
15
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
16
Coal tar Approved Phase 4 8007-45-2
17
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
18
Cyproterone acetate Approved, Investigational Phase 4 427-51-0 9880
19
Tetracycline Approved, Vet_approved, Withdrawn Phase 4 60-54-8 5353990
20
Sarecycline Approved, Investigational Phase 4 1035654-66-0
21
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
22
Desogestrel Approved Phase 4 54024-22-5 40973
23
Azelaic acid Approved Phase 4 123-99-9 2266
24
Ethanol Approved Phase 4 64-17-5 702
25
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
26
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
27
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
28
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
29
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
30
Sage Approved Phase 4
31
Trifarotene Approved, Investigational Phase 4 895542-09-3 11518241
32
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
33
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
34
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
35
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
36
Caffeine Approved Phase 4 58-08-2 2519
37
Chamomile Approved, Experimental, Investigational Phase 4
38
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
40
Isotretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4, 4759-48-2 5538 444795 5282379
41
Nadifloxacin Investigational Phase 4 124858-35-1
42
Rosemary Experimental Phase 4
43
Resveratrol Investigational Phase 4 501-36-0 445154
44 Folic Acid Antagonists Phase 4
45 Hormones Phase 4
46 Hormone Antagonists Phase 4
47 Anti-Inflammatory Agents Phase 4
48 Clindamycin, tretinoin drug combination Phase 4
49 Adapalene, Benzoyl Peroxide Drug Combination Phase 4
50 Analgesics Phase 4

Interventional clinical trials:

(show top 50) (show all 703)
# Name Status NCT ID Phase Drugs
1 Efficacy & Safety of Clindamycin Phosphase 1.2% and Tretinoin 0.025% Gel vs. Vehicle for the Treatment of Acne and Acne-Induced Post Inflammatory Hyperpigmentation in Patients With Skin of Color Unknown status NCT01111994 Phase 4 Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
2 Vitamin D and Its Topical Analogues: A Possible Role in the Pathogenesis and Treatment of Acne Vulgaris Unknown status NCT03866447 Phase 4 Vitamin D analog;Adapalene
3 Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks Unknown status NCT00988026 Phase 4 Minocycline vs Lymecycline
4 Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel) Unknown status NCT00237978 Phase 4 Adapalen
5 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
6 A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris. Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
7 A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment of Facial Acne Vulgaris Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
8 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
9 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris Completed NCT00841776 Phase 4 Duac;Ziana gel
10 Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne Completed NCT00658112 Phase 4 Benzoyl Peroxide
11 A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use Completed NCT02052752 Phase 4 3% Benzoyl Peroxide;3% Benzoyl Peroxide Placebo;Neutrogena Rapid Clear®
12 Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects Completed NCT02735421 Phase 4 ABPO Forte Gel;Vehicle gel
13 Multicentric, Parallel, Randomized, Double Blind Study Under Dermatological Control to Evaluate the Anti-acne Efficacy of a Dermo-cosmetic Product (Fla 688977 33) Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus This Treatment Associated With a Standard Moisturizer (Hydréane légère, Cosmétique Active International) During a 12-week Application Period in Male and Female Subjects Presenting With Mild to Moderate Acne Completed NCT03832647 Phase 4 Salicylic Acid
14 Acne Free vs. Proactiv for the Treatment of Moderately Severe Acne Vulgaris Completed NCT00913185 Phase 4 Acne Free, Proactiv
15 Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females Completed NCT01387048 Phase 4 skinoren;differin
16 An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris Completed NCT00696449 Phase 4 Adapalene
17 A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris Completed NCT00660985 Phase 4 Adapalene
18 Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris Completed NCT02589405 Phase 4 Benzoyl Peroxide
19 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris Completed NCT00835198 Phase 4 Dapsone; Tretinoin;Tretinoin
20 A Multi-center, Randomized, Evaluator-blind, Parallel-group Evaluation of the Efficacy, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Topical Treatment of Facial Acne Vulgaris Completed NCT00757523 Phase 4 Epiduo Gel;Duac Gel
21 Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris Completed NCT01951417 Phase 4 Adapalene/BPO Gel
22 A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris Completed NCT00671749 Phase 4 adapalene gel, 0.3%;clindamycin/benzoyl peroxide gel
23 An Open-label Study to Investigate the Efficacy and Tolerability of Aczone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color Completed NCT03681470 Phase 4 Aczone Gel
24 Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne Completed NCT00837213 Phase 4 Benzoyl peroxide with clindamycin;Benzoyl peroxide with clindamycin and doxycycline
25 Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
26 Pilot Study of Tolerability and Effectivity Following Application of Two Combination Topical Acne Products Clindamycin 1% and 0.025% Tretinoin Gel (Acnatac® Gel), Adapalen 0,1% and Benzoyl Peroxide 2,5% Gel (Epiduo® Gel) Completed NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
27 A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-week Treatment Switched to Tazorac® Cream, 0.1% 6-week Treatment in Patients With Acne Vulgaris Completed NCT00469755 Phase 4 Adapalene Gel, 0.1%;Tazarotene Cream, 0.1%;Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
28 Serum Homocysteine Level in Acne Patients Before and After Oral Isotretinoin Completed NCT05529888 Phase 4 Isotretinoin
29 Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin. Completed NCT01909713 Phase 4 Facial Cleanser and Moisturizer SPF 30
30 Effect of Patient Education on Treatment Adherence and Satisfaction Among Acne Patients Receiving Once-daily Epiduo Gel Treatment in Primary Care Clinics Completed NCT02307266 Phase 4
31 Single-blind, Multicenter, Parallel, Comparative, Randomized, Phase 4 Clinical Trial for the Evaluation of the Quality of Life, Efficacy and Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris. Completed NCT00807014 Phase 4 Duac Gel;Differin gel
32 An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris. Completed NCT00437151 Phase 4
33 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Doryx Tablets Compared to Doxycycline Hyclate in the Treatment of Acne Vulgaris. Completed NCT00635609 Phase 4 Doxycycline hyclate (Doryx);Doxycycline hyclate
34 Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
35 A Multi-Center Clinical Trial to Evaluate the Efficacy of Two Acne Treatments Completed NCT02755545 Phase 4 Product A (adapalene);Product B (salicylic acid)
36 Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
37 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
38 Clinical Quality Assurance Study: Fractional CO2 Treatment of Acne Scars in Asians Completed NCT00748462 Phase 4
39 U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects With Acne Completed NCT01706250 Phase 4
40 Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial Completed NCT02721173 Phase 4 Tazarotene 0.1% gel plus clindamycin 1% gel;Adapalene 0.1% gel plus clindamycin 1% gel
41 Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
42 An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model Completed NCT00714714 Phase 4 Adapalene Gel;Tretinoin Gel
43 U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne Completed NCT01706263 Phase 4 MAXCLARITY II (2.5% BPO) Foam Cleanser;MAXCLARITY II (2.5% BPO) Foam Treatment;MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
44 A Multi-centre, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
45 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Completed NCT02032407 Phase 4 Dapsone Gel
46 An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Completed NCT02959970 Phase 4 dapsone gel
47 A Single-blind, Randomized, Comparative Split-face Study Evaluating the Tolerability of Clindamycin and Benzoyl Peroxide Gel to Benzoyl Peroxide/Adapalene Gel in the Treatment of Acne Vulgaris. Completed NCT00964223 Phase 4 Clindamycin and benzoyl peroxide gel (Duac® Topical Gel);benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
48 An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model Completed NCT00952523 Phase 4 Tretinoin Facial Gel;Adapalene/Benzoyl Peroxide Facial Gel
49 A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study To Compare Efficacy and Safety of Trifarotene (CD5789) Cream When Used Withan Oral Antibiotic for the Treatment of Severe Acne Vulgaris Completed NCT04451330 Phase 4 Trifarotene cream;Doxycycline hyclate;Trifarotene Vehicle;Doxycycline Placebo
50 U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne Completed NCT02524665 Phase 4

Search NIH Clinical Center for Acne

Cochrane evidence based reviews: acne vulgaris

Sources

Genetic Tests for Acne

About this section

Genetic tests related to Acne:

# Genetic test Affiliating Genes
1 Acne 28
Sources

Anatomical Context for Acne

About this section

Organs/tissues related to Acne:

MalaCards : Skin, Ovary, Thyroid, Whole Blood, Liver, Brain, Lung
Sources

Publications for Acne

About this section

Articles related to Acne:

(show top 50) (show all 17768)
# Title Authors PMID Year
1
Sulforaphene Attenuates Cutibacterium acnes-Induced Inflammation. 62 41
36437519 2022
2
Carbon Peeling Laser Treatment to Improve Skin Texture, Pores and Acne Lesions: A Retrospective Study. 62 41
36422207 2022
3
Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. 62 41
36439142 2022
4
[Modern aspects of acne pathogenesis]. 53 62
20482694 2010
5
Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. 53 62
18704103 2009
6
TLR2 and TLR4 polymorphisms are not associated with acne vulgaris. 53 62
17033191 2006
7
Defensins and acne. 53 62
14568392 2003
8
Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. 53 62
11710922 2001
9
Peroxisomes in dermatology. Part II. 53 62
11907843 2001
10
Peroxisomes in dermatology. Part I. 53 62
11685671 2001
11
Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. 53 62
9557222 1998
12
Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. 53 62
9068725 1997
13
Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. 53 62
8689881 1996
14
Androgen levels in women using a single implant of nomegestrol acetate. 53 62
8631188 1996
15
Inflammatory levels of interleukin 1 alpha are present in the majority of open comedones in acne vulgaris. 53 62
1830734 1991
16
A Review of Laser Therapies for the Treatment of Scarring and Vascular Anomalies. 62
35951024 2023
17
Thymus mastichina (L.) L. and Cistus ladanifer L. for skin application: chemical characterization and in vitro bioactivity assessment. 62
36243295 2023
18
Immunomodulatory efficacy of Cousinia thomsonii C.B. Clarke in ameliorating inflammatory cascade expressions. 62
36116611 2023
19
Long-pulsed Nd: YAG laser (1064 nm) versus intralesional botulinum toxin type (A) in acne vulgaris therapy: a split face study. 62
36468835 2022
20
Prevalence of skin diseases and prognosis of atopic dermatitis in primary school children in populated areas of Japan from 2010 to 2019: The Asa Study in Hiroshima, Japan. 62
36120740 2022
21
An update on the prevalence, chronicity, and severity of atopic dermatitis and the associated epidemiological risk factors in the Singapore/Malaysia Chinese young adult population: A detailed description of the Singapore/Malaysia Cross-Sectional Genetics Epidemiology Study (SMCGES) cohort. 62
36438192 2022
22
A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis. 62
36345408 2022
23
Red Light-Mediated Photoredox Catalysis Triggers Nitric Oxide Release for Treatment of Cutibacterium Acne Induced Intervertebral Disc Degeneration. 62
36469724 2022
24
Photodynamic therapy with light emitting fabrics: a review. 62
34797414 2022
25
[Clinical analysis of 49 cases of non-inflammasome related conditions]. 62
36444428 2022
26
Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. 62
36257374 2022
27
Analysis of corneal topographic and densitometric properties in patients receiving systemic isotretinoin therapy. 62
36433791 2022
28
Facial dermatoses induced by face masks: A systematic review and meta-analysis of observational studies. 62
35980367 2022
29
Two phenotypes of chronic recurrent multifocal osteomyelitis with different patterns of bone involvement. 62
36456962 2022
30
Prevalence of Metabolic Syndrome and Insulin Resistance in Adult Patients with Acne: Association with Traditional Cardiovascular Risk Factors and Acne Severity. 62
36472551 2022
31
Serum and salivary adipsin levels and its association with insulin resistance in acne vulgaris patients. 62
36459421 2022
32
Therapeutic potential of adipose tissue-derivatives in modern dermatology. 62
35102608 2022
33
The "Hand as Foot" teaching method in whole-body bone scintigraphy of synovitis-acne-pustulosishyperostosis-osteitis syndrome. 62
35773110 2022
34
Human skin microbiota in health and disease: The cutaneous communities' interplay in equilibrium and dysbiosis: The cutaneous communities' interplay in equilibrium and dysbiosis. 62
34919288 2022
35
Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa. 62
35881108 2022
36
Nitrofurantoin and Minocycline-Associated Vasculitic Neuropathy: Case Reports and Literature Review. 62
36409339 2022
37
Health effects of androgen abuse: a review of the HAARLEM study. 62
35938779 2022
38
The role of biofilm formation in the pathogenesis and antimicrobial susceptibility of Cutibacteriumacnes. 62
34950868 2022
39
Psychodermatologic pathology in adolescents: findings from the Colombian National Mental Health Survey. 62
33090967 2022
40
D-optimal mixture design for optimization of topical dapsone niosomes: in vitro characterization and in vivo activity against Cutibacterium acnes. 62
35266431 2022
41
Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations. 62
36220974 2022
42
Preparation and optimization of aloe ferox gel loaded with Finasteride-Oregano oil nanocubosomes for treatment of alopecia. 62
35019794 2022
43
Mask-related skin changes among healthcare workers in a community-based hospital. 62
36028224 2022
44
Complete Genome Sequence of Lactobacillus helveticus VHProbi Y21, Isolated from Kimchi. 62
36453928 2022
45
SUPPLEMENT INDIVIDUAL ARTICLE: Bridging the Gap: Optimizing Skin Care in Acne Treatment. 62
36468960 2022
46
Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents. 62
36473894 2022
47
The increasing importance of the gut microbiome in acne vulgaris. 62
35711021 2022
48
How I Do It: Treatment of Papular Acne Scars of the Nose. 62
36449884 2022
49
[Rapid screening of 14 antibacterial drugs in anti-acne cosmetics using ion mobility spectrometry coupled with solid-phase extraction]. 62
36450352 2022
50
Analyzing trends in treatment of acne vulgaris and adherence to the American Academy of Dermatology guidelines: A retrospective study. 62
36248202 2022
Sources

Variations for Acne

About this section
Sources

Expression for Acne

About this section
Search GEO for disease gene expression data for Acne.
Sources

Pathways for Acne

About this section

Pathways related to Acne according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.8 CAT CXCL8 DEFB1 DEFB4A IL1A IL1B
2
Prolactin Signaling 64
Show member pathways
 13.35 IGF1 IL1A IL1B NCSTN PRL PSEN1
3
Toll-like receptor signaling pathway 74
Show member pathways
 12.82 TNF TLR2 IL1B IL1A CXCL8
4
Signaling by Receptor Tyrosine Kinases 66
12.81 PSENEN PSEN1 NCSTN INS IGF1
5
NF-KappaB Family Pathway 64
Show member pathways
 12.68 IGF1 IL1A IL1B TLR2 TNF
6
Alzheimer's disease and miRNA effects 74
Show member pathways
 12.67 TNF PSENEN PSEN1 NCSTN INS IL1B
7
IL-1 Family Signaling Pathways 65
Show member pathways
 12.58 TNF TLR2 IL1B IL1A CXCL8
8
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.48 CXCL8 IL1B TLR2 TNF
9
Toll Comparative Pathway 64
Show member pathways
 12.29 TNF IL1B IL1A CXCL8
10
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.13 CXCL8 IL1A IL1B TNF
11
Bacterial infections in CF airways 22
Show member pathways
 12.13 TNF TLR2 IL1B IL1A DEFB4A CXCL8
12
Neuroinflammation and glutamatergic signaling 74
12.06 TNF IL1B IL1A IGF1
13
Signaling by ERBB4 66
Show member pathways
 12.03 PSENEN PSEN1 PRL NCSTN
14
Development Notch Signaling Pathway 22
Show member pathways
 11.96 IL1A NCSTN PSEN1 PSENEN
15
Spinal cord injury 74
11.94 TNF IL1B IL1A CXCL8
16
Interleukin-4 and Interleukin-13 signaling 66
11.88 TNF IL1B IL1A CXCL8
17
Allograft rejection 74
11.79 TNF IL1B IL1A CXCL8
18
Burn wound healing 74
11.73 TNF IL1B CXCL8
19
Signaling by NOTCH3 66
Show member pathways
 11.72 PSENEN PSEN1 NCSTN
20
p75(NTR)-mediated signaling 61
Show member pathways
 11.67 PSENEN PSEN1 NCSTN
21
miRNAs involvement in the immune response in sepsis 74
11.64 TNF IL1A CXCL8
22
IL 10 signaling pathway 67
11.64 TNF IL1B IL1A
23
DYRK1A 74
11.63 PSENEN PSEN1 NCSTN
24
Inflammatory bowel disease signaling 74
Show member pathways
 11.61 TNF TLR2 IL1A
25
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.6 TNF IL1B IL1A CXCL8
26
Lung fibrosis 74
11.58 TNF IL1B IGF1 CXCL8
27
Senescence and autophagy in cancer 74
11.57 INS IL1B IL1A IGF1 CXCL8
28
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.54 TNF DEFB4A CXCL8
29
MSP-RON Signaling 64
11.5 TNF TLR2 IL1B
30
Presenilin action in Notch and Wnt signaling 61
11.48 PSENEN PSEN1 NCSTN
31
Nonalcoholic fatty liver disease 74
11.47 TNF INS IL1A
32
Amyotrophic lateral sclerosis (ALS) 74
11.34 TNF SOD1 CAT
33
Interleukin-10 signaling 66
11.34 TNF IL1B IL1A CXCL8
34
IL-10 Pathway 64
11.32 TNF IL1B IL1A
35
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.28 IGF1 IL1A IL1B TNF
36
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.24 CXCL8 IL1B TNF
37
Cytokines and inflammatory response 74
11.21 TNF IL1B IL1A
38
Oligodendrocyte specification and differentiation, leading to myelin components for CNS 74
11.18 TNF IL1B IGF1
39
A-beta Plaque Formation and APP Metabolism 65
11.07 PSENEN PSEN1 NCSTN
40
G-protein signaling_Rap2B regulation pathway 22
11 TNF IL1B IL1A IGF1 CXCL8
41
Prostaglandin signaling 74
10.7 TNF IL1B IL1A CXCL8
42
Arsenic metabolism and reactive oxygen species generation 74
10.69 SOD1 CAT
43
Inclusion body myositis 74
10.63 PSENEN PSEN1 NCSTN
44
Notch Pathway 70
10.35 PSENEN PSEN1
45
Cells and molecules involved in local acute inflammatory response 74
Show member pathways
 10.35 TNF CXCL8
46
Syndecan-3-mediated signaling events 61
10.23 PSENEN PSEN1 NCSTN CXCL8
Sources

GO Terms for Acne

About this section

Cellular components related to Acne according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.23 TNF SOD1 SHBG PRL INS IL1B
2 extracellular space GO:0005615 10.02 CAT CXCL8 DEFB1 DEFB4A GGT1 IGF1
3 obsolete integral component of presynaptic membrane GO:0099056 9.43 PSENEN PSEN1 NCSTN
4 gamma-secretase complex GO:0070765 9.1 PSENEN PSEN1 NCSTN

Biological processes related to Acne according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.39 TNF TLR2 PSTPIP1 IL1B IL1A CXCL8
2 negative regulation of gene expression GO:0010629 10.36 TNF PSEN1 INS IGF1 CXCL8
3 response to xenobiotic stimulus GO:0009410 10.33 TNF SRD5A1 SOD1 GATA6 CAT
4 immune response GO:0006955 10.29 CXCL8 DEFB1 DEFB4A IL1A IL1B TLR2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.22 TNF TLR2 INS IL1B CAT
6 positive regulation of interleukin-6 production GO:0032755 10.21 IL1A IL1B TLR2 TNF
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.17 TNF INS IGF1 CAT
8 positive regulation of gene expression GO:0010628 10.16 CXCL8 IGF1 IL1A IL1B INS PSEN1
9 positive regulation of cell division GO:0051781 10.15 IL1B IL1A CAT
10 cellular response to amyloid-beta GO:1904646 10.13 IGF1 PSEN1 TNF
11 defense response to Gram-positive bacterium GO:0050830 10.13 DEFB1 DEFB4A IL1B TLR2 TNF
12 lipopolysaccharide-mediated signaling pathway GO:0031663 10.11 TNF TLR2 IL1B
13 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.1 TNF IL1B IL1A
14 regulation of multicellular organism growth GO:0040014 10.06 SOD1 PRL IGF1
15 positive regulation of chemokine production GO:0032722 10.05 TNF TLR2 IL1B
16 membrane protein ectodomain proteolysis GO:0006509 10.05 PSENEN PSEN1 NCSTN
17 positive regulation of glycolytic process GO:0045821 10.03 IGF1 INS PSEN1
18 negative regulation of lipid catabolic process GO:0050995 10.02 TNF INS IL1B
19 ectopic germ cell programmed cell death GO:0035234 10.01 SOD1 IL1B IL1A
20 astrocyte activation GO:0048143 9.97 TNF PSEN1 IL1B
21 positive regulation of immature T cell proliferation in thymus GO:0033092 9.96 IL1B IL1A
22 response to ozone GO:0010193 9.96 IL1A CAT
23 response to L-ascorbic acid GO:0033591 9.95 IL1A CAT
24 positive regulation of fever generation GO:0031622 9.94 TNF IL1B
25 defense response GO:0006952 9.93 CXCL8 DEFB1 DEFB4A TNF
26 amyloid precursor protein catabolic process GO:0042987 9.93 PSENEN PSEN1 NCSTN
27 sequestering of triglyceride GO:0030730 9.92 TNF IL1B
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.9 TNF IL1B
29 fever generation GO:0001660 9.89 IL1B IL1A
30 cell activation GO:0001775 9.88 TNF TLR2 IGF1
31 amyloid precursor protein metabolic process GO:0042982 9.88 PSENEN PSEN1 NCSTN
32 amyloid-beta formation GO:0034205 9.85 PSENEN PSEN1 NCSTN
33 Notch receptor processing GO:0007220 9.8 PSENEN PSEN1 NCSTN
34 positive regulation of catalytic activity GO:0043085 9.76 SOD1 PSENEN PSEN1 NCSTN
35 positive regulation of cytokine production GO:0001819 9.61 TNF SOD1 INS IL1B IL1A
36 positive regulation of mitotic nuclear division GO:0045840 9.32 TNF INS IL1B IL1A IGF1
Sources

Sources for Acne

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....